Lukas Marti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lukas Marti has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Rene Warschkow
Department of General, Visceral, Endocrine and Transplant Surgery, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland
8 shared publications - Bruno M. Schmied
Department of General, Visceral, Endocrine and Transplant Surgery, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland
6 shared publications - Walter Brunner
Department of General, Visceral, Endocrine and Transplant Surgery, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland
6 shared publications Bruno M. Schmied
Department of General, Visceral, Endocrine and Transplantation Surgery, Kantonsspital St. Gallen, St. Gallen, Switzerland
5 shared publicationsRene Warschkow
Department of General, Visceral, Endocrine and Transplantation Surgery, Kantonsspital St. Gallen, Switzerland
5 shared publicationsStefan Post
Universitätsklinik Mannheim, Mannheim, Deutschland
4 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by Springer Nature in Techniques in Coloproctology
- Vol. 30 (1) , 40
Does the management of anastomotic leakage after rectal cancer resection affect long-term oncological survival? A retrospective propensity score-adjusted cohort study
Background The International Study Group of Rectal Cancer (ISREC) provides a classification of anastomotic leakage (AL). This classification categorises the severity of AL according to its clinical management. The aim of this study was to determine whether AL and its management influence survival. Methods Patients who underwent elective mesorectal excision (PME or TME) for primary rectal cancer stages I–III and who underwent anastomosis were included. A retrospective analysis of clinical data retrieved from a prospectively conducted database was performed. The primary endpoint was cancer-specific survival (CSS). Risk factors were adjusted by propensity score matching (PSM). The secondary endpoints were overall survival (OS), disease-free survival (DFS), and local recurrence-free rate (RFR). Results A total of 942 patients underwent surgery between 1991 and 2020 and were followed for a mean of 71.9 (SD 48.5) months. AL occurred in 141 patients (15.0%). Twenty-three patients had grade A AL (16.3%), 48 patients had grade B AL (34.0%), and 70 patients had grade C AL (49.6%). AL had no significant negative influence on the 5-year propensity score-adjusted survival rate for CSS (no AL 92.2%, AL 87.9%, p = 0.161), but did so on OS (no AL 78.6%, AL 66.9%, p = 0.005), DFS (no AL 72.9%, AL 60.9%, p = 0.011), and RFR (no AL 94.2%, AL 88.5%, p = 0.047). The severity of AL did not have a significant influence on CSS (p = 0.642). Conclusions AL had a negative influence on OS, DFS, and RFR. Whether aggressive surgical clinical management of AL has any influence on CSS remains unclear. Clinical trial registration The study was registered at ClinicalTrials.gov (NCT06059924).
- 6 March 2026
- Published by Springer Nature in Techniques in Coloproctology
- Vol. 30 (1) , 40
Open AccessDoes the management of anastomotic leakage after rectal cancer resection affect long-term oncological survival? A retrospective propensity score-adjusted cohort study
Background The International Study Group of Rectal Cancer (ISREC) provides a classification of anastomotic leakage (AL). This classification categorises the severity of AL according to its clinical management. The aim of this study was to determine whether AL and its management influence survival. Methods Patients who underwent elective mesorectal excision (PME or TME) for primary rectal cancer stages I–III and who underwent anastomosis were included. A retrospective analysis of clinical data retrieved from a prospectively conducted database was performed. The primary endpoint was cancer-specific survival (CSS). Risk factors were adjusted by propensity score matching (PSM). The secondary endpoints were overall survival (OS), disease-free survival (DFS), and local recurrence-free rate (RFR). Results A total of 942 patients underwent surgery between 1991 and 2020 and were followed for a mean of 71.9 (SD 48.5) months. AL occurred in 141 patients (15.0%). Twenty-three patients had grade A AL (16.3%), 48 patients had grade B AL (34.0%), and 70 patients had grade C AL (49.6%). AL had no significant negative influence on the 5-year propensity score-adjusted survival rate for CSS (no AL 92.2%, AL 87.9%, p = 0.161), but did so on OS (no AL 78.6%, AL 66.9%, p = 0.005), DFS (no AL 72.9%, AL 60.9%, p = 0.011), and RFR (no AL 94.2%, AL 88.5%, p = 0.047). The severity of AL did not have a significant influence on CSS (p = 0.642). Conclusions AL had a negative influence on OS, DFS, and RFR. Whether aggressive surgical clinical management of AL has any influence on CSS remains unclear. Clinical trial registration The study was registered at ClinicalTrials.gov (NCT06059924).
- Open Access
- 8 September 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (5)
Implementation of guideline recommendations in coloanal anastomosis: results from the Tender Loving Care in Coloanal Anastomosis survey
- 8 September 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (5)
Open AccessImplementation of guideline recommendations in coloanal anastomosis: results from the Tender Loving Care in Coloanal Anastomosis survey
- Open Access
- 30 April 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1-12
Does transanal total mesorectal excision (taTME) result in better quality of life and functional outcomes than traditional TME does? A retrospective propensity score-adjusted cohort study
Purpose The improved prognosis of rectal cancer through modern therapeutic approaches raises questions regarding quality of life (QoL) and functional outcomes. In this study, we compared post-transanal total mesorectal excision (taTME) short- and long-term QoL and functional outcomes with those after abdominal TME (abTME). Methods Prospective data from patients who underwent elective taTME or abTME for stage I-III rectal cancer followed by anastomosis were retrospectively propensity score-adjusted. The primary endpoint, QoL, was assessed with the European Organization for Research and Treatment of Cancer core questionnaire (EORTC QLQ-C30). Functional outcomes were the secondary endpoints. Results Among 494 patients during 2013–2022, 187 patients who underwent taTME and 62 patients who underwent abTME were included. QoL was worse after taTME at isolated time points: overall QoL (after 3 years: 72 vs. 82 points, p = 0.017) and QLQ-total (after 3 years: 81 vs. 87 points, p = 0.028; after 4 years: 82 vs. 89 points, p = 0.012). After propensity score matching, the between-group differences were still significant but smaller: overall QoL − 6 points, p = 0.021; QLQ-total − 5 points, p = 0.026. Conclusion The differences reported at isolated time points have questionable clinical relevance. Therefore, taTME and traditional abTME seem to have comparable long-term QoL and functional outcomes. Clinical trial registration ClinicalTrials.gov, NCT06505863, https://clinicaltrials.gov/search?id=NCT06505863.
- 30 April 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1-12
Open AccessDoes transanal total mesorectal excision (taTME) result in better quality of life and functional outcomes than traditional TME does? A retrospective propensity score-adjusted cohort study
Purpose The improved prognosis of rectal cancer through modern therapeutic approaches raises questions regarding quality of life (QoL) and functional outcomes. In this study, we compared post-transanal total mesorectal excision (taTME) short- and long-term QoL and functional outcomes with those after abdominal TME (abTME). Methods Prospective data from patients who underwent elective taTME or abTME for stage I-III rectal cancer followed by anastomosis were retrospectively propensity score-adjusted. The primary endpoint, QoL, was assessed with the European Organization for Research and Treatment of Cancer core questionnaire (EORTC QLQ-C30). Functional outcomes were the secondary endpoints. Results Among 494 patients during 2013–2022, 187 patients who underwent taTME and 62 patients who underwent abTME were included. QoL was worse after taTME at isolated time points: overall QoL (after 3 years: 72 vs. 82 points, p = 0.017) and QLQ-total (after 3 years: 81 vs. 87 points, p = 0.028; after 4 years: 82 vs. 89 points, p = 0.012). After propensity score matching, the between-group differences were still significant but smaller: overall QoL − 6 points, p = 0.021; QLQ-total − 5 points, p = 0.026. Conclusion The differences reported at isolated time points have questionable clinical relevance. Therefore, taTME and traditional abTME seem to have comparable long-term QoL and functional outcomes. Clinical trial registration ClinicalTrials.gov, NCT06505863, https://clinicaltrials.gov/search?id=NCT06505863.
- Open Access
- 20 February 2024
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 39 (1) , 1-17
Is survival after transanal total mesorectal excision (taTME) worse than that after traditional total mesorectal excision? A retrospective propensity score-adjusted cohort study
Purpose: Transanal total mesorectal excision (taTME) was developed to provide better vision during resection of the mesorectum. Conflicting results have shown an increase in local recurrence and shorter survival after taTME. This study compared the outcomes of taTME and abdominal (open, laparoscopic, robotic) total mesorectal excision (abTME). Methods: Patients who underwent taTME or abTME for stages I–III rectal cancer and who received an anastomosis were included. A retrospective analysis of a prospectively conducted database was performed. The primary endpoints were overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Risk factors were adjusted by propensity score matching (PSM). The secondary endpoints were local recurrence rates and combined poor pathological outcomes. Results: From 2012 to 2020, a total of 189 patients underwent taTME, and 119 underwent abTME; patients were followed up for a mean of 54.7 (SD 24.2) and 78.4 (SD 34.8) months, respectively (p < 0.001). The 5-year survival rates after taTME and abTME were not significantly different after PSM: OS: 78.2% vs. 88.6% (p = 0.073), CSS: 87.4% vs. 92.1% (p = 0.359), and DFS: 69.3% vs. 80.9% (p = 0.104), respectively. No difference in the local recurrence rate was observed (taTME, n = 10 (5.3%); abTME, n = 10 (8.4%); p = 0.280). Combined poor pathological outcomes were more frequent after abTME (n = 36, 34.3%) than after taTME (n = 35, 19.6%) (p = 0.006); this difference was nonsignificant according to multivariate analysis (p = 0.404). Conclusion: taTME seems to be a good treatment option for patients with rectal cancer and is unlikely to significantly affect local recurrence or survival. However, further investigations concerning the latter are warranted. Trial registration: ClinicalTrials.gov (NCT0496910).
- 20 February 2024
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 39 (1) , 1-17
Open AccessIs survival after transanal total mesorectal excision (taTME) worse than that after traditional total mesorectal excision? A retrospective propensity score-adjusted cohort study
Purpose: Transanal total mesorectal excision (taTME) was developed to provide better vision during resection of the mesorectum. Conflicting results have shown an increase in local recurrence and shorter survival after taTME. This study compared the outcomes of taTME and abdominal (open, laparoscopic, robotic) total mesorectal excision (abTME). Methods: Patients who underwent taTME or abTME for stages I–III rectal cancer and who received an anastomosis were included. A retrospective analysis of a prospectively conducted database was performed. The primary endpoints were overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Risk factors were adjusted by propensity score matching (PSM). The secondary endpoints were local recurrence rates and combined poor pathological outcomes. Results: From 2012 to 2020, a total of 189 patients underwent taTME, and 119 underwent abTME; patients were followed up for a mean of 54.7 (SD 24.2) and 78.4 (SD 34.8) months, respectively (p < 0.001). The 5-year survival rates after taTME and abTME were not significantly different after PSM: OS: 78.2% vs. 88.6% (p = 0.073), CSS: 87.4% vs. 92.1% (p = 0.359), and DFS: 69.3% vs. 80.9% (p = 0.104), respectively. No difference in the local recurrence rate was observed (taTME, n = 10 (5.3%); abTME, n = 10 (8.4%); p = 0.280). Combined poor pathological outcomes were more frequent after abTME (n = 36, 34.3%) than after taTME (n = 35, 19.6%) (p = 0.006); this difference was nonsignificant according to multivariate analysis (p = 0.404). Conclusion: taTME seems to be a good treatment option for patients with rectal cancer and is unlikely to significantly affect local recurrence or survival. However, further investigations concerning the latter are warranted. Trial registration: ClinicalTrials.gov (NCT0496910).
- Open Access
- 6 October 2023
- Published by Springer Nature in Research Square
Is survival after transanal total mesorectal excision (taTME) worse than that after traditional total mesorectal excision? A Retrospective Propensity Score-Adjusted Cohort Study
Purpose:Transanal total mesorectal excision (taTME) was developed to provide better vision during resection of the mesorectum. Conflicting results have shown an increase in local recurrences and shorter survival after taTME. This study compares the outcomes of taTME and abdominal (open, laparoscopic, robotic) total mesorectal excision (abTME). Methods:Patients who underwent taTME or abTME for stage I-III rectal cancer and received an anastomosis were included. A retrospective analysis of a prospectively conducted database was performed. The primary endpoints were overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Risk factors were adjusted by propensity score matching (PSM). The secondary endpoints were local recurrence rates and combined poor pathological outcomes. Results: From 2012 to 2020, a total of 189 patients underwent taTME, and 119 underwent abTME; patients were followed up for a median of 53.3 [IQR 35.9-71.8] and 84.0 [IQR 50.2-107.9] months, respectively (pp=0.073); CSS: 87.4% vs. 92.1% (p=0.359); and DFS: 69.3% vs. 80.9%, respectively (p=0.104). No difference in the local recurrence rate was observed (taTME n=10 (5.3%), abTME n=10 (8.4%); p=0.280). Combined poor pathological outcomes were more frequent after abTME (n=36, 34.3%) than after taTME (n=35, 19.6%) (p=0.006); this difference was nonsignificant in multivariate analysis (p=0.404). Conclusion: The findings reveal that taTME is a good treatment option for rectal cancer; it likely does not significantly affect survival or local recurrence, and it might have a positive influence on specimen quality.
- 6 October 2023
- Published by Springer Nature in Research Square
Open AccessIs survival after transanal total mesorectal excision (taTME) worse than that after traditional total mesorectal excision? A Retrospective Propensity Score-Adjusted Cohort Study
Purpose:Transanal total mesorectal excision (taTME) was developed to provide better vision during resection of the mesorectum. Conflicting results have shown an increase in local recurrences and shorter survival after taTME. This study compares the outcomes of taTME and abdominal (open, laparoscopic, robotic) total mesorectal excision (abTME). Methods:Patients who underwent taTME or abTME for stage I-III rectal cancer and received an anastomosis were included. A retrospective analysis of a prospectively conducted database was performed. The primary endpoints were overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Risk factors were adjusted by propensity score matching (PSM). The secondary endpoints were local recurrence rates and combined poor pathological outcomes. Results: From 2012 to 2020, a total of 189 patients underwent taTME, and 119 underwent abTME; patients were followed up for a median of 53.3 [IQR 35.9-71.8] and 84.0 [IQR 50.2-107.9] months, respectively (pp=0.073); CSS: 87.4% vs. 92.1% (p=0.359); and DFS: 69.3% vs. 80.9%, respectively (p=0.104). No difference in the local recurrence rate was observed (taTME n=10 (5.3%), abTME n=10 (8.4%); p=0.280). Combined poor pathological outcomes were more frequent after abTME (n=36, 34.3%) than after taTME (n=35, 19.6%) (p=0.006); this difference was nonsignificant in multivariate analysis (p=0.404). Conclusion: The findings reveal that taTME is a good treatment option for rectal cancer; it likely does not significantly affect survival or local recurrence, and it might have a positive influence on specimen quality.
- 20 September 2021
- Published by Springer Nature in coloproctology
- Vol. 43 (6) , 425-426
Transanale Abdeckelung des intersphinktären Raums (TROPIS)
- 20 September 2021
- Published by Springer Nature in coloproctology
- Vol. 43 (6) , 425-426
Transanale Abdeckelung des intersphinktären Raums (TROPIS)
- 2 December 2020
- Published by Springer Nature in coloproctology
- Vol. 42 (6) , 439-440
Analfissur
- 6 May 2020
- Published by Springer Nature in Techniques in Coloproctology
- Vol. 24 (7) , 773-774
A dark swelling in a hidden place
- 6 May 2020
- Published by Springer Nature in Techniques in Coloproctology
- Vol. 24 (7) , 773-774
A dark swelling in a hidden place
- 22 April 2020
- Published by Springer Nature in coloproctology
- Vol. 42 (2) , 90-196
S3-Leitlinie: Analfissur
Zusammenfassung: Die Analfissur ist eine der häufigsten Pathologien, welche sich dem Proktologen präsentiert. Entsprechend ist es wichtig, verlässliche Leitlinien dazu zu entwickeln. Die aktuelle Leitlinie wurde anhand eines systematischen Literaturreview von einem interdisziplinären Expertengremium diskutiert und verabschiedet.Die akute Analfissur, soll auf Grund ihrer hohen Selbstheilungstendenz konservativ behandelt werden. Die Heilung wird am besten durch die Einnahme von Ballaststoff reicher Ernährung und einer medikamentösen Relaxation durch Kalziumkanal-Antagonisten (CCA) unterstützt. Zur Behandlung der chronischen Analfissur (CAF), soll den Patienten eine medikamentöse Behandlung zur „chemischen Sphinkterotomie“ mittels topischer CCA oder Nitraten angeboten werden. Bei Versagen dieser Therapie, kann zur Relaxation des inneren Analsphinkters Botulinumtoxin injiziert werden. Es ist belegt, dass die operativen Therapien effektiver sind. Deshalb kann eine Operation schon als primäre Therapie oder nach erfolgloser medikamentöser Therapie erfolgen. Die Fissurektomie, evtl. mit zusätzlicher Botulinumtoxin Injektion oder Lappendeckung, ist die Operation der Wahl. Obwohl die laterale Internus Sphinkterotomie die CAF effektiver heilt, bleibt diese wegen dem höheren Risiko für eine postoperative Stuhlinkontinenz eine Option für Einzelfälle.
- 22 April 2020
- Published by Springer Nature in coloproctology
- Vol. 42 (2) , 90-196
S3-Leitlinie: Analfissur
Zusammenfassung: Die Analfissur ist eine der häufigsten Pathologien, welche sich dem Proktologen präsentiert. Entsprechend ist es wichtig, verlässliche Leitlinien dazu zu entwickeln. Die aktuelle Leitlinie wurde anhand eines systematischen Literaturreview von einem interdisziplinären Expertengremium diskutiert und verabschiedet.Die akute Analfissur, soll auf Grund ihrer hohen Selbstheilungstendenz konservativ behandelt werden. Die Heilung wird am besten durch die Einnahme von Ballaststoff reicher Ernährung und einer medikamentösen Relaxation durch Kalziumkanal-Antagonisten (CCA) unterstützt. Zur Behandlung der chronischen Analfissur (CAF), soll den Patienten eine medikamentöse Behandlung zur „chemischen Sphinkterotomie“ mittels topischer CCA oder Nitraten angeboten werden. Bei Versagen dieser Therapie, kann zur Relaxation des inneren Analsphinkters Botulinumtoxin injiziert werden. Es ist belegt, dass die operativen Therapien effektiver sind. Deshalb kann eine Operation schon als primäre Therapie oder nach erfolgloser medikamentöser Therapie erfolgen. Die Fissurektomie, evtl. mit zusätzlicher Botulinumtoxin Injektion oder Lappendeckung, ist die Operation der Wahl. Obwohl die laterale Internus Sphinkterotomie die CAF effektiver heilt, bleibt diese wegen dem höheren Risiko für eine postoperative Stuhlinkontinenz eine Option für Einzelfälle.
- Open Access
- 30 January 2019
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 25 (1) , 159-170
Success and Complication Rates After Sacral Neuromodulation for Fecal Incontinence and Constipation: A Single-center Follow-up Study
Bernhard Widmann, Christian Galata, Rene Warschkow, Ulrich Beutner, Önder Ögredici, Franc H Hetzer, Bruno M Schmied, Stefan Post, and Lukas Marti. J Neurogastroenterol Motil 2019;25:159-70. https://doi.org/10.5056/jnm17106
- 30 January 2019
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 25 (1) , 159-170
Open AccessSuccess and Complication Rates After Sacral Neuromodulation for Fecal Incontinence and Constipation: A Single-center Follow-up Study
Bernhard Widmann, Christian Galata, Rene Warschkow, Ulrich Beutner, Önder Ögredici, Franc H Hetzer, Bruno M Schmied, Stefan Post, and Lukas Marti. J Neurogastroenterol Motil 2019;25:159-70. https://doi.org/10.5056/jnm17106